NCT00490139
Version 99 to 100 · Novartis Pharmaceuticals
Patch inspector
Manual review pending.
eligibility_criteria_changeprimary_outcome_any_changesecondary_outcome_any_change [
{
"path": "/protocolSection/statusModule/primaryCompletionDateStruct/date",
"signal": "timeline_significant_shift",
"category": "timeline_significant_shift",
"new_type": "ESTIMATED",
"old_type": "ESTIMATED",
"severity": "medium",
"direction": "later",
"new_value": "2013-07",
"old_value": "2013-01",
"delta_days": 181,
"date_struct": "primaryCompletionDateStruct",
"new_precision": "month",
"old_precision": "month"
},
{
"path": "/protocolSection/statusModule/completionDateStruct/date",
"signal": "timeline_major_slip",
"category": "timeline_major_slip",
"new_type": "ESTIMATED",
"old_type": "ESTIMATED",
"severity": "medium",
"direction": "later",
"new_value": "2018-10",
"old_value": "2013-05",
"delta_days": 1979,
"date_struct": "completionDateStruct",
"new_precision": "month",
"old_precision": "month"
}
] 088ba67b27c18d9e2916829602c95283f66ca17fb910ab619e8f6faed25f4710/protocolSection/outcomesModule/primaryOutcomes/0/measure primary_outcome_any_change Any add/remove/replace under primary outcome measures is critical review priority. Disease-free survival will be analysed after 1388 events, using a two-sided stratified log-rank test.
Disease-free survival
/protocolSection/eligibilityModule/eligibilityCriteria eligibility_criteria_change Eligibility criteria changes can alter the studied population. <p>Inclusion Criteria:</p><ul><li>Age ≥ 18 years</li><li>Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;</li><li><p>Non-metastatic operable primary invasive adenocarcinoma of the breast fulfilling the following:</p><ol><li>Histologically confirmed</li><li>Adequately excised (exceptions: patients who have 'non-resectable' deep margin invasion are eligible provided they have had or will receive radiotherapy encompassing the region concerned; patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumour bed);</li><li>Axilla dissected; sentinel node sampling is allowed provided that axillary dissection follows confirmation of a positive sentinel node; sentinel node sampling alone is NOT acceptable after neoadjuvant chemotherapy (in patients receiving neoadjuvant chemotherapy lymph node status will be considered unknown, regardless of the results of post-chemotherapy axillary dissection);</li><li>Axillary node positive patient OR node negative patient with a tumour greater than or equal to 1.0 cm in greatest diameter. For clarification, isolated tumour cells (ITC) are considered pN0 and micrometastases are considered pN1</li></ol></li><li>Known hormone receptor status (ER/PgR or ER alone)</li><li>For Designs 1 and 2: Patients must have received at least four cycles of an approved anthracycline-based (neo-) adjuvant chemotherapy regimen or listed as an exception in Table 5.</li></ul><p>For Design 1: Randomization must be performed no longer than 12 weeks from day 1 of the last chemotherapy cycle after obtaining a post-chemotherapy LVEF ≥ 50. Study treatment must start no more than 14 days after randomization For Design 2: Randomization must be performed no longer than 6 weeks from day 1 of the last anthracycline-containing chemotherapy cycle after obtaining a post-anthracycline chemotherapy LVEF ≥ 50. Study treatment must start no more than 14 days after randomization and must be concurrent with taxanes.</p><p>For Design 2B: Randomisation must be performed no longer than 8 weeks from definitive surgery. Non-anthracycline platinum containing regimen (docetaxel and carboplatin) and study treatment must start concomitantly and no more than 14 days after randomisation.</p><ul><li>Baseline LVEF ≥50% measured by echocardiography or MUGA scan. For Design 1 and Design 2 - after completion of all anthracycline-based (neo-) adjuvant chemotherapy and prior to the targeted therapy(ies); for Design 2B - prior to targeted therapy(ies) and chemotherapy (docetaxel and carboplatin)</li><li>Over expression and/or amplification of HER2 in the invasive component of the primary tumour (in case of neoadjuvant treatment, tissue sample used for HER2 testing should be collected before neoadjuvant treatment starts), according to one of the following definitions [Wolff et al 2007] and confirmed by central laboratory prior to randomization:</li><li>3+ over expression by IHC (> 30% of invasive tumour cells);</li><li>2+ or 3+ (in 30% or less neoplastic cells) over expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification;</li><li>HER2 gene amplification by FISH/CISH ( > 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > than 2.2.) Patients with a negative or equivocal overall result (FISH test ratio of ≤ 2.2, ≤ 6.0 HER2 gene copies per nucleus) and staining scores of 0, 1+, 2+ or 3+ (in 30% or less neoplastic cells) by IHC are not eligible for participation in the trial.</li></ul><p>Equivocal local results may be submitted for a final determination by the central laboratory.</p><ul><li>Completion of all necessary baseline laboratory and radiological investigations</li><li>Signed written informed consent (approved by an Independent Ethics Committee (IEC) and obtained prior to any study specific screening procedures).</li></ul><p>Exclusion Criteria:</p><ul><li>History of any prior (ipsi- and/or contralateral) invasive breast carcinoma;</li><li>Past (less than 10 years) or current history of malignant neoplasms, except for curatively treated 1) basal and squamous cell carcinoma of the skin or 2) carcinoma in situ of the cervix.</li></ul><p>NOTE: Patients with a prior malignancy diagnosed greater than 10 years in the past who have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic therapy (chemotherapy or endocrine) are eligible for the study. Patients with any prior diagnosis of breast cancer or melanoma, at any time, are excluded from this study.</p><ul><li>Any clinically staged T4 tumour, including inflammatory breast cancer;</li><li>Bilateral tumours;</li><li>This exclusion criterion has been removed as of protocol amendment 1.</li></ul><p>NOTE: multifocal/multicentric tumours are permitted:</p><ul><li>If the patient is node-negative: one of the lesions must be equal or greater than 1.0 cm (sum of the lesion diameters is not acceptable) AND must have positive HER2 status centrally-confirmed;</li><li>If patient is node-positive: lesion size does not matter BUT one of the lesions must have HER2 positivity centrally-confirmed. If several lesions are found to be HER2 positive locally, the largest lesion should be considered for central review.</li><li>Maximum cumulative dose of doxorubicin >360mg/m² or maximum cumulative dose of epirubicin >720mg/m² or any prior anthracyclines unrelated to the present breast cancer;</li><li>(Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell support;</li><li>Any prior mediastinal irradiation except internal mammary node irradiation for the present breast cancer;</li><li>Patients with positive or suspicious internal mammary nodes identified by sentinel node technique which have not been irradiated or will not be irradiated, or patients with supraclavicular lymph node involvement (confirmed by fine needle aspirate or biopsy);</li><li>Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for breast cancer;</li><li>Concurrent anti-cancer treatment, except hormonal therapy or radiotherapy for the present breast cancer;</li><li>Concurrent anti-cancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the Executive Committee:</li><li>Serious cardiac illness or medical conditions including but not confined to:</li></ul><p>History of documented congestive heart failure (CHF) or systolic dysfunction (LVEF <50%); High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled); Angina pectoris requiring antianginal medication; Clinically significant valvular heart disease; Evidence of transmural infarction on ECG; Poorly controlled hypertension (e.g. systolic >180mm Hg or diastolic >100mm Hg);</p><ul><li>Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness;</li><li>Any of the following abnormal laboratory tests immediately prior to randomization:</li></ul><p>serum total bilirubin >1.5 x upper limit of normal (ULN), in the case of known Gilbert's syndrome, a higher serum total bilirubin (<2 X ULN) is allowed; alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) >2.5 x ULN; alkaline phosphatase (ALP) > 2.5 x ULN; serum creatinine >2.0 x ULN; total white blood cell count (WBC) <2.5 x 10^9/L; absolute neutrophil count <1.5 x 10^9/L; platelets <100 x 10^9/L.</p><ul><li>Unresolved or unstable serious adverse events from prior adjuvant chemotherapy or radiotherapy;</li><li>Malabsorption syndrome, any disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication. Subjects with ulcerative colitis are also excluded;</li><li>Pregnant, lactating or women of childbearing potential without a negative pregnancy test - urine or serum - within 7 days prior to randomization, irrespective of the method of contraception used, including tubal ligation;</li><li>Women of childbearing potential and male participants with partners of child bearing potential, including women whose last menstrual period was <12 months ago (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during study treatment (adequate contraceptive measures: intra-uterine device, barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not indicated in this patient population);</li><li>Concomitant use of CYP3A4 inhibitors or inducers.</li></ul>
<p>Inclusion Criteria:</p><ul><li>Age ≥ 18 years</li><li>Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;</li><li><p>Non-metastatic operable primary invasive adenocarcinoma of the breast fulfilling the following:</p><ol><li>Histologically confirmed</li><li>Adequately excised (exceptions: patients who have 'non-resectable' deep margin invasion are eligible provided they have had or will receive radiotherapy encompassing the region concerned; patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumour bed);</li><li>Axilla dissected; sentinel node sampling is allowed provided that axillary dissection follows confirmation of a positive sentinel node; sentinel node sampling alone is NOT acceptable after neoadjuvant chemotherapy (in patients receiving neoadjuvant chemotherapy lymph node status will be considered unknown, regardless of the results of post-chemotherapy axillary dissection);</li><li>Axillary node positive patient OR node negative patient with a tumour greater than or equal to 1.0 cm in greatest diameter. For clarification, isolated tumour cells (ITC) are considered pN0 and micrometastases are considered pN1</li></ol></li><li>Known hormone receptor status (ER/PgR or ER alone)</li><li>For Designs 1 and 2: Patients must have received at least four cycles of an approved anthracycline-based (neo-) adjuvant chemotherapy regimen or listed as an exception in Table 5 of the protocol.</li></ul><p>For Design 1: Randomization must be performed no longer than 12 weeks from day 1 of the last chemotherapy cycle after obtaining a post-chemotherapy LVEF ≥ 50. Study treatment must start no more than 14 days after randomization For Design 2: Randomization must be performed no longer than 6 weeks from day 1 of the last anthracycline-containing chemotherapy cycle after obtaining a post-anthracycline chemotherapy LVEF ≥ 50. Study treatment must start no more than 14 days after randomization and must be concurrent with taxanes.</p><p>For Design 2B: Randomisation must be performed no longer than 8 weeks from definitive surgery. Non-anthracycline platinum containing regimen (docetaxel and carboplatin) and study treatment must start concomitantly and no more than 14 days after randomisation.</p><ul><li>Baseline LVEF ≥50% measured by echocardiography or MUGA scan. For Design 1 and Design 2 - after completion of all anthracycline-based (neo-) adjuvant chemotherapy and prior to the targeted therapy(ies); for Design 2B - prior to targeted therapy(ies) and chemotherapy (docetaxel and carboplatin)</li><li>Over expression and/or amplification of HER2 in the invasive component of the primary tumour (in case of neoadjuvant treatment, tissue sample used for HER2 testing should be collected before neoadjuvant treatment starts), according to one of the following definitions [Wolff et al 2007] and confirmed by central laboratory prior to randomization:</li><li>3+ over expression by IHC (> 30% of invasive tumour cells);</li><li>2+ or 3+ (in 30% or less neoplastic cells) over expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification;</li><li>HER2 gene amplification by FISH/CISH ( > 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > than 2.2.) Patients with a negative or equivocal overall result (FISH test ratio of ≤ 2.2, ≤ 6.0 HER2 gene copies per nucleus) and staining scores of 0, 1+, 2+ or 3+ (in 30% or less neoplastic cells) by IHC are not eligible for participation in the trial.</li></ul><p>Equivocal local results may be submitted for a final determination by the central laboratory.</p><ul><li>Completion of all necessary baseline laboratory and radiological investigations</li><li>Signed written informed consent (approved by an Independent Ethics Committee (IEC) and obtained prior to any study specific screening procedures).</li></ul><p>Exclusion Criteria:</p><ul><li>History of any prior (ipsi- and/or contralateral) invasive breast carcinoma;</li><li>Past (less than 10 years) or current history of malignant neoplasms, except for curatively treated 1) basal and squamous cell carcinoma of the skin or 2) carcinoma in situ of the cervix.</li></ul><p>NOTE: Patients with a prior malignancy diagnosed greater than 10 years in the past who have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic therapy (chemotherapy or endocrine) are eligible for the study. Patients with any prior diagnosis of breast cancer or melanoma, at any time, are excluded from this study.</p><ul><li>Any clinically staged T4 tumour, including inflammatory breast cancer;</li><li>Bilateral tumours;</li><li>This exclusion criterion has been removed as of protocol amendment 1.</li></ul><p>NOTE: multifocal/multicentric tumours are permitted:</p><ul><li>If the patient is node-negative: one of the lesions must be equal or greater than 1.0 cm (sum of the lesion diameters is not acceptable) AND must have positive HER2 status centrally-confirmed;</li><li>If patient is node-positive: lesion size does not matter BUT one of the lesions must have HER2 positivity centrally-confirmed. If several lesions are found to be HER2 positive locally, the largest lesion should be considered for central review.</li><li>Maximum cumulative dose of doxorubicin >360mg/m² or maximum cumulative dose of epirubicin >720mg/m² or any prior anthracyclines unrelated to the present breast cancer;</li><li>(Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell support;</li><li>Any prior mediastinal irradiation except internal mammary node irradiation for the present breast cancer;</li><li>Patients with positive or suspicious internal mammary nodes identified by sentinel node technique which have not been irradiated or will not be irradiated, or patients with supraclavicular lymph node involvement (confirmed by fine needle aspirate or biopsy);</li><li>Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for breast cancer;</li><li>Concurrent anti-cancer treatment, except hormonal therapy or radiotherapy for the present breast cancer;</li><li>Concurrent anti-cancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the Executive Committee:</li><li>Serious cardiac illness or medical conditions including but not confined to:</li></ul><p>History of documented congestive heart failure (CHF) or systolic dysfunction (LVEF <50%); High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled); Angina pectoris requiring antianginal medication; Clinically significant valvular heart disease; Evidence of transmural infarction on ECG; Poorly controlled hypertension (e.g. systolic >180mm Hg or diastolic >100mm Hg);</p><ul><li>Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness;</li><li>Any of the following abnormal laboratory tests immediately prior to randomization:</li></ul><p>serum total bilirubin >1.5 x upper limit of normal (ULN), in the case of known Gilbert's syndrome, a higher serum total bilirubin (<2 X ULN) is allowed; alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) >2.5 x ULN; alkaline phosphatase (ALP) > 2.5 x ULN; serum creatinine >2.0 x ULN; total white blood cell count (WBC) <2.5 x 10^9/L; absolute neutrophil count <1.5 x 10^9/L; platelets <100 x 10^9/L.</p><ul><li>Unresolved or unstable serious adverse events from prior adjuvant chemotherapy or radiotherapy;</li><li>Malabsorption syndrome, any disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication. Subjects with ulcerative colitis are also excluded;</li><li>Pregnant, lactating or women of childbearing potential without a negative pregnancy test - urine or serum - within 7 days prior to randomization, irrespective of the method of contraception used, including tubal ligation;</li><li>Women of childbearing potential and male participants with partners of child bearing potential, including women whose last menstrual period was <12 months ago (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during study treatment (adequate contraceptive measures: intra-uterine device, barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not indicated in this patient population);</li><li>Concomitant use of CYP3A4 inhibitors or inducers.</li></ul>
/protocolSection/outcomesModule/secondaryOutcomes/0/measure secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority. Overall survival; Time to recurrence; Time to distant recurrence; Incidence of brain metastases
Time to recurrence
/protocolSection/outcomesModule/secondaryOutcomes/1 secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority. {
"measure": "Time to distant recurrence"
} /protocolSection/outcomesModule/secondaryOutcomes/2 secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority. {
"measure": "Incidence of brain metastases as first site of breast cancer recurrence"
} /protocolSection/outcomesModule/secondaryOutcomes/3 secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority. {
"measure": "Safety and Tolerability"
} /protocolSection/outcomesModule/secondaryOutcomes/4 secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority. {
"measure": "Conduct analyses separately for cohorts defined by the presence or absence of cMyc gene amplification"
} /protocolSection/outcomesModule/secondaryOutcomes/5 secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority. {
"measure": "Conduct analyses separately for cohorts defined by the expression levels of PTEN"
} /protocolSection/outcomesModule/secondaryOutcomes/6 secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority. {
"measure": "Conduct analyses separately for cohorts defined by the presence or absence of p95HER2 domain"
} /protocolSection/outcomesModule/secondaryOutcomes/7 secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority. {
"measure": "Overall survival"
} /protocolSection/statusModule/primaryCompletionDateStruct/date primary_completion_timeline_change Primary completion date changes are operational timeline signals. 2013-01
2013-07
/protocolSection/statusModule/completionDateStruct/date completion_timeline_change Completion date changes are operational timeline signals. 2013-05
2018-10
/protocolSection/contactsLocationsModule/locations/7 {
"zip": "72401",
"city": "Jonesboro",
"state": "Arkansas",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.8423,
"lon": -90.70428
}
} /protocolSection/contactsLocationsModule/locations/9 {
"zip": "72401",
"city": "Jonesboro",
"state": "Arkansas",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.8423,
"lon": -90.70428
}
} /protocolSection/contactsLocationsModule/locations/15 {
"zip": "94538",
"city": "Fremont",
"state": "California",
"status": "COMPLETED",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 37.54827,
"lon": -121.98857
}
} /protocolSection/contactsLocationsModule/locations/17 {
"zip": "94538",
"city": "Fremont",
"state": "California",
"status": "COMPLETED",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 37.54827,
"lon": -121.98857
}
} /protocolSection/contactsLocationsModule/locations/21 {
"zip": "92093-0987",
"city": "La Jolla",
"state": "California",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 32.84727,
"lon": -117.2742
}
} /protocolSection/contactsLocationsModule/locations/23 {
"zip": "92093-0987",
"city": "La Jolla",
"state": "California",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 32.84727,
"lon": -117.2742
}
} /protocolSection/contactsLocationsModule/locations/33/status NOT_YET_RECRUITING
COMPLETED
/protocolSection/contactsLocationsModule/locations/50 {
"zip": "80220",
"city": "Denver",
"state": "Colorado",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 39.73915,
"lon": -104.9847
}
} /protocolSection/contactsLocationsModule/locations/52 {
"zip": "80220",
"city": "Denver",
"state": "Colorado",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 39.73915,
"lon": -104.9847
}
} /protocolSection/contactsLocationsModule/locations/81 {
"zip": "33805",
"city": "Lakeland",
"state": "Florida",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 28.03947,
"lon": -81.9498
}
} /protocolSection/contactsLocationsModule/locations/83 {
"zip": "33805",
"city": "Lakeland",
"state": "Florida",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 28.03947,
"lon": -81.9498
}
} /protocolSection/contactsLocationsModule/locations/103 {
"zip": "30165",
"city": "Rome",
"state": "Georgia",
"status": "COMPLETED",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 34.25704,
"lon": -85.16467
}
} /protocolSection/contactsLocationsModule/locations/105/status COMPLETED
NOT_YET_RECRUITING
/protocolSection/contactsLocationsModule/locations/105/city Rome
Savannah
/protocolSection/contactsLocationsModule/locations/105/zip 30165
31405
/protocolSection/contactsLocationsModule/locations/105/geoPoint/lat 34.25704
32.08354
/protocolSection/contactsLocationsModule/locations/105/geoPoint/lon -85.16467
-81.09983
/protocolSection/contactsLocationsModule/locations/107 {
"zip": "31405",
"city": "Savannah",
"state": "Georgia",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 32.08354,
"lon": -81.09983
}
} /protocolSection/contactsLocationsModule/locations/124 {
"zip": "60611",
"city": "Chicago",
"state": "Illinois",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.85003,
"lon": -87.65005
}
} /protocolSection/contactsLocationsModule/locations/126 {
"zip": "60611",
"city": "Chicago",
"state": "Illinois",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.85003,
"lon": -87.65005
}
} /protocolSection/contactsLocationsModule/locations/149 {
"zip": "61350",
"city": "Ottawa",
"state": "Illinois",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.34559,
"lon": -88.84258
}
} /protocolSection/contactsLocationsModule/locations/151 {
"zip": "61350",
"city": "Ottawa",
"state": "Illinois",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.34559,
"lon": -88.84258
}
} /protocolSection/contactsLocationsModule/locations/156 {
"zip": "61615",
"city": "Peoria",
"state": "Illinois",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 40.69365,
"lon": -89.58899
}
} /protocolSection/contactsLocationsModule/locations/158 {
"zip": "61615",
"city": "Peoria",
"state": "Illinois",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 40.69365,
"lon": -89.58899
}
} /protocolSection/contactsLocationsModule/locations/159 {
"zip": "61354",
"city": "Peru",
"state": "Illinois",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.32753,
"lon": -89.12897
}
} /protocolSection/contactsLocationsModule/locations/161 {
"zip": "61354",
"city": "Peru",
"state": "Illinois",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.32753,
"lon": -89.12897
}
} /protocolSection/contactsLocationsModule/locations/172 {
"zip": "46202",
"city": "Indianapolis",
"state": "Indiana",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 39.76838,
"lon": -86.15804
}
} /protocolSection/contactsLocationsModule/locations/174 {
"zip": "46202",
"city": "Indianapolis",
"state": "Indiana",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 39.76838,
"lon": -86.15804
}
} /protocolSection/contactsLocationsModule/locations/183 {
"zip": "52722",
"city": "Bettendorf",
"state": "Iowa",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.52448,
"lon": -90.51569
}
} /protocolSection/contactsLocationsModule/locations/185 {
"zip": "52722",
"city": "Bettendorf",
"state": "Iowa",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.52448,
"lon": -90.51569
}
} /protocolSection/contactsLocationsModule/locations/191 {
"zip": "50314",
"city": "Des Moines",
"state": "Iowa",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.60054,
"lon": -93.60911
}
} /protocolSection/contactsLocationsModule/locations/193 {
"zip": "50314",
"city": "Des Moines",
"state": "Iowa",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.60054,
"lon": -93.60911
}
} /protocolSection/contactsLocationsModule/locations/230 {
"zip": "70809",
"city": "Baton Rouge",
"state": "Louisiana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 30.44332,
"lon": -91.18747
}
} /protocolSection/contactsLocationsModule/locations/232 {
"zip": "70112",
"city": "New Orleans",
"state": "Louisiana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 29.95465,
"lon": -90.07507
}
} /protocolSection/contactsLocationsModule/locations/234 {
"zip": "70112",
"city": "New Orleans",
"state": "Louisiana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 29.95465,
"lon": -90.07507
}
} /protocolSection/contactsLocationsModule/locations/236 {
"zip": "04074",
"city": "Scarborough",
"state": "Maine",
"status": "COMPLETED",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 43.57814,
"lon": -70.32172
}
} /protocolSection/contactsLocationsModule/locations/238 {
"zip": "04074",
"city": "Scarborough",
"state": "Maine",
"status": "COMPLETED",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 43.57814,
"lon": -70.32172
}
} /protocolSection/contactsLocationsModule/locations/265/status NOT_YET_RECRUITING
RECRUITING
/protocolSection/contactsLocationsModule/locations/268 {
"zip": "49007",
"city": "Kalamazoo",
"state": "Michigan",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 42.29171,
"lon": -85.58723
}
} /protocolSection/contactsLocationsModule/locations/270 {
"zip": "49007",
"city": "Kalamazoo",
"state": "Michigan",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 42.29171,
"lon": -85.58723
}
} /protocolSection/contactsLocationsModule/locations/276 {
"zip": "49085",
"city": "Saint Joseph",
"state": "Michigan",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 42.10976,
"lon": -86.48002
}
} /protocolSection/contactsLocationsModule/locations/278 {
"zip": "49085",
"city": "Saint Joseph",
"state": "Michigan",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 42.10976,
"lon": -86.48002
}
} /protocolSection/contactsLocationsModule/locations/285 {
"zip": "55805",
"city": "Duluth",
"state": "Minnesota",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 46.78327,
"lon": -92.10658
}
} /protocolSection/contactsLocationsModule/locations/287 {
"zip": "55805",
"city": "Duluth",
"state": "Minnesota",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 46.78327,
"lon": -92.10658
}
} /protocolSection/contactsLocationsModule/locations/299 {
"zip": "56303",
"city": "Saint Cloud",
"state": "Minnesota",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 45.5608,
"lon": -94.16249
}
} /protocolSection/contactsLocationsModule/locations/301/status RECRUITING
NOT_YET_RECRUITING
/protocolSection/contactsLocationsModule/locations/301/city Saint Cloud
Saint Louis Park
/protocolSection/contactsLocationsModule/locations/301/zip 56303
55416
/protocolSection/contactsLocationsModule/locations/301/geoPoint/lat 45.5608
44.9483
/protocolSection/contactsLocationsModule/locations/301/geoPoint/lon -94.16249
-93.34801
/protocolSection/contactsLocationsModule/locations/303 {
"zip": "55416",
"city": "Saint Louis Park",
"state": "Minnesota",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 44.9483,
"lon": -93.34801
}
} /protocolSection/contactsLocationsModule/locations/333 {
"zip": "63141",
"city": "St Louis",
"state": "Missouri",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 38.62727,
"lon": -90.19789
}
} /protocolSection/contactsLocationsModule/locations/335/city St Louis
Billings
/protocolSection/contactsLocationsModule/locations/335/state Missouri
Montana
/protocolSection/contactsLocationsModule/locations/335/zip 63141
59101
/protocolSection/contactsLocationsModule/locations/335/geoPoint/lat 38.62727
45.78329
/protocolSection/contactsLocationsModule/locations/335/geoPoint/lon -90.19789
-108.50069
/protocolSection/contactsLocationsModule/locations/337 {
"zip": "59101",
"city": "Billings",
"state": "Montana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 45.78329,
"lon": -108.50069
}
} /protocolSection/contactsLocationsModule/locations/339 {
"zip": "59405",
"city": "Great Falls",
"state": "Montana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.50024,
"lon": -111.30081
}
} /protocolSection/contactsLocationsModule/locations/341 {
"zip": "59405",
"city": "Great Falls",
"state": "Montana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.50024,
"lon": -111.30081
}
} /protocolSection/contactsLocationsModule/locations/374 {
"zip": "08240",
"city": "Pomona",
"state": "New Jersey",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 39.47845,
"lon": -74.57516
}
} /protocolSection/contactsLocationsModule/locations/381 {
"zip": "87106",
"city": "Albuquerque",
"state": "New Mexico",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.08449,
"lon": -106.65114
}
} /protocolSection/contactsLocationsModule/locations/383 {
"zip": "87106",
"city": "Albuquerque",
"state": "New Mexico",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.08449,
"lon": -106.65114
}
} /protocolSection/contactsLocationsModule/locations/393 {
"zip": "11030",
"city": "Manhasset",
"state": "New York",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 40.79788,
"lon": -73.69957
}
} /protocolSection/contactsLocationsModule/locations/395 {
"zip": "11030",
"city": "Manhasset",
"state": "New York",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 40.79788,
"lon": -73.69957
}
} /protocolSection/contactsLocationsModule/locations/416 {
"zip": "27607",
"city": "Raleigh",
"state": "North Carolina",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.7721,
"lon": -78.63861
}
} /protocolSection/contactsLocationsModule/locations/418 {
"zip": "27607",
"city": "Raleigh",
"state": "North Carolina",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.7721,
"lon": -78.63861
}
} /protocolSection/contactsLocationsModule/locations/422 {
"zip": "58501",
"city": "Bismarck",
"state": "North Dakota",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 46.80833,
"lon": -100.78374
}
} /protocolSection/contactsLocationsModule/locations/424/city Bismarck
Fargo
/protocolSection/contactsLocationsModule/locations/424/zip 58501
58122
/protocolSection/contactsLocationsModule/locations/424/geoPoint/lat 46.80833
46.87719
/protocolSection/contactsLocationsModule/locations/424/geoPoint/lon -100.78374
-96.7898
/protocolSection/contactsLocationsModule/locations/426 {
"zip": "58122",
"city": "Fargo",
"state": "North Dakota",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 46.87719,
"lon": -96.7898
}
} /protocolSection/contactsLocationsModule/locations/537 {
"zip": "38301",
"city": "Jackson",
"state": "Tennessee",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.61452,
"lon": -88.81395
}
} /protocolSection/contactsLocationsModule/locations/539/city Jackson
Knoxville
/protocolSection/contactsLocationsModule/locations/539/zip 38301
37909
/protocolSection/contactsLocationsModule/locations/539/geoPoint/lat 35.61452
35.96064
/protocolSection/contactsLocationsModule/locations/539/geoPoint/lon -88.81395
-83.92074
/protocolSection/contactsLocationsModule/locations/541 {
"zip": "37909",
"city": "Knoxville",
"state": "Tennessee",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.96064,
"lon": -83.92074
}
} /protocolSection/contactsLocationsModule/locations/556/status NOT_YET_RECRUITING
RECRUITING
/protocolSection/contactsLocationsModule/locations/593 {
"zip": "98122",
"city": "Seattle",
"state": "Washington",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.60621,
"lon": -122.33207
}
} /protocolSection/contactsLocationsModule/locations/595 {
"zip": "98122",
"city": "Seattle",
"state": "Washington",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.60621,
"lon": -122.33207
}
} /protocolSection/contactsLocationsModule/locations/599 {
"zip": "98405",
"city": "Tacoma",
"state": "Washington",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.25288,
"lon": -122.44429
}
} /protocolSection/contactsLocationsModule/locations/601 {
"zip": "98405",
"city": "Tacoma",
"state": "Washington",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.25288,
"lon": -122.44429
}
} /protocolSection/contactsLocationsModule/locations/615 {
"zip": "54301",
"city": "Green Bay",
"state": "Wisconsin",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 44.51916,
"lon": -88.01983
}
} /protocolSection/contactsLocationsModule/locations/617 {
"zip": "54301",
"city": "Green Bay",
"state": "Wisconsin",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 44.51916,
"lon": -88.01983
}
} /protocolSection/contactsLocationsModule/locations/624 {
"zip": "53233",
"city": "Milwaukee",
"state": "Wisconsin",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 43.0389,
"lon": -87.90647
}
} /protocolSection/contactsLocationsModule/locations/626 {
"zip": "53233",
"city": "Milwaukee",
"state": "Wisconsin",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 43.0389,
"lon": -87.90647
}
} /protocolSection/contactsLocationsModule/locations/702 {
"zip": "9000",
"city": "Ghent",
"status": "COMPLETED",
"country": "Belgium",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 51.05,
"lon": 3.71667
}
} /protocolSection/contactsLocationsModule/locations/704 {
"zip": "9000",
"city": "Ghent",
"status": "COMPLETED",
"country": "Belgium",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 51.05,
"lon": 3.71667
}
} /protocolSection/contactsLocationsModule/locations/789/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/790/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/791/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/792/status RECRUITING
COMPLETED
/protocolSection/contactsLocationsModule/locations/793/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/795/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/796/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/797/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/798/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/800/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/801/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/802/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/804/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/805/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/806/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/807/status RECRUITING
COMPLETED
/protocolSection/contactsLocationsModule/locations/808/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/810/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/812/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/813/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/816/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/817/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/818/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/819/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/820/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/821/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/822/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/824/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/825/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/826/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/828/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/829/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/830/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/831/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/832/status RECRUITING
COMPLETED
/protocolSection/contactsLocationsModule/locations/834/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/835/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/838/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/839/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/840/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/841/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/842/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/843/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1051/status RECRUITING
COMPLETED
/protocolSection/contactsLocationsModule/locations/1052/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1053/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1054/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1055/status RECRUITING
COMPLETED
/protocolSection/contactsLocationsModule/locations/1056/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1143/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1145/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1146/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1148/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1150/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1151/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1152/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1153/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1155/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1158/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1159/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1160/status RECRUITING
ACTIVE_NOT_RECRUITING
/protocolSection/contactsLocationsModule/locations/1293 {
"zip": "8091",
"city": "Zurich",
"status": "NOT_YET_RECRUITING",
"country": "Switzerland",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.36667,
"lon": 8.55
}
} /protocolSection/contactsLocationsModule/locations/1295 {
"zip": "8091",
"city": "Zurich",
"status": "NOT_YET_RECRUITING",
"country": "Switzerland",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.36667,
"lon": 8.55
}
} /protocolSection/statusModule/statusVerifiedDate 2010-06
2010-07
/protocolSection/statusModule/lastUpdateSubmitDate 2010-06-17
2010-07-01
/protocolSection/statusModule/lastUpdatePostDateStruct/date 2010-06-22
2010-07-05
[
{
"op": "replace",
"path": "/protocolSection/statusModule/statusVerifiedDate",
"value": "2010-07"
},
{
"op": "replace",
"path": "/protocolSection/statusModule/primaryCompletionDateStruct/date",
"value": "2013-07"
},
{
"op": "replace",
"path": "/protocolSection/statusModule/completionDateStruct/date",
"value": "2018-10"
},
{
"op": "replace",
"path": "/protocolSection/statusModule/lastUpdateSubmitDate",
"value": "2010-07-01"
},
{
"op": "replace",
"path": "/protocolSection/statusModule/lastUpdatePostDateStruct/date",
"value": "2010-07-05"
},
{
"op": "replace",
"path": "/protocolSection/outcomesModule/primaryOutcomes/0/measure",
"value": "Disease-free survival"
},
{
"op": "replace",
"path": "/protocolSection/outcomesModule/secondaryOutcomes/0/measure",
"value": "Time to recurrence"
},
{
"op": "add",
"path": "/protocolSection/outcomesModule/secondaryOutcomes/1",
"value": {
"measure": "Time to distant recurrence"
}
},
{
"op": "add",
"path": "/protocolSection/outcomesModule/secondaryOutcomes/2",
"value": {
"measure": "Incidence of brain metastases as first site of breast cancer recurrence"
}
},
{
"op": "add",
"path": "/protocolSection/outcomesModule/secondaryOutcomes/3",
"value": {
"measure": "Safety and Tolerability"
}
},
{
"op": "add",
"path": "/protocolSection/outcomesModule/secondaryOutcomes/4",
"value": {
"measure": "Conduct analyses separately for cohorts defined by the presence or absence of cMyc gene amplification"
}
},
{
"op": "add",
"path": "/protocolSection/outcomesModule/secondaryOutcomes/5",
"value": {
"measure": "Conduct analyses separately for cohorts defined by the expression levels of PTEN"
}
},
{
"op": "add",
"path": "/protocolSection/outcomesModule/secondaryOutcomes/6",
"value": {
"measure": "Conduct analyses separately for cohorts defined by the presence or absence of p95HER2 domain"
}
},
{
"op": "add",
"path": "/protocolSection/outcomesModule/secondaryOutcomes/7",
"value": {
"measure": "Overall survival"
}
},
{
"op": "replace",
"path": "/protocolSection/eligibilityModule/eligibilityCriteria",
"value": "<p>Inclusion Criteria:</p><ul><li>Age ≥ 18 years</li><li>Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;</li><li><p>Non-metastatic operable primary invasive adenocarcinoma of the breast fulfilling the following:</p><ol><li>Histologically confirmed</li><li>Adequately excised (exceptions: patients who have 'non-resectable' deep margin invasion are eligible provided they have had or will receive radiotherapy encompassing the region concerned; patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumour bed);</li><li>Axilla dissected; sentinel node sampling is allowed provided that axillary dissection follows confirmation of a positive sentinel node; sentinel node sampling alone is NOT acceptable after neoadjuvant chemotherapy (in patients receiving neoadjuvant chemotherapy lymph node status will be considered unknown, regardless of the results of post-chemotherapy axillary dissection);</li><li>Axillary node positive patient OR node negative patient with a tumour greater than or equal to 1.0 cm in greatest diameter.\nFor clarification, isolated tumour cells (ITC) are considered pN0 and micrometastases are considered pN1</li></ol></li><li>Known hormone receptor status (ER/PgR or ER alone)</li><li>For Designs 1 and 2: Patients must have received at least four cycles of an approved anthracycline-based (neo-) adjuvant chemotherapy regimen or listed as an exception in Table 5 of the protocol.</li></ul><p>For Design 1: Randomization must be performed no longer than 12 weeks from day 1 of the last chemotherapy cycle after obtaining a post-chemotherapy LVEF ≥ 50.\nStudy treatment must start no more than 14 days after randomization For Design 2: Randomization must be performed no longer than 6 weeks from day 1 of the last anthracycline-containing chemotherapy cycle after obtaining a post-anthracycline chemotherapy LVEF ≥ 50.\nStudy treatment must start no more than 14 days after randomization and must be concurrent with taxanes.</p><p>For Design 2B: Randomisation must be performed no longer than 8 weeks from definitive surgery.\nNon-anthracycline platinum containing regimen (docetaxel and carboplatin) and study treatment must start concomitantly and no more than 14 days after randomisation.</p><ul><li>Baseline LVEF ≥50% measured by echocardiography or MUGA scan.\nFor Design 1 and Design 2 - after completion of all anthracycline-based (neo-) adjuvant chemotherapy and prior to the targeted therapy(ies); for Design 2B - prior to targeted therapy(ies) and chemotherapy (docetaxel and carboplatin)</li><li>Over expression and/or amplification of HER2 in the invasive component of the primary tumour (in case of neoadjuvant treatment, tissue sample used for HER2 testing should be collected before neoadjuvant treatment starts), according to one of the following definitions [Wolff et al 2007] and confirmed by central laboratory prior to randomization:</li><li>3+ over expression by IHC (> 30% of invasive tumour cells);</li><li>2+ or 3+ (in 30% or less neoplastic cells) over expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification;</li><li>HER2 gene amplification by FISH/CISH ( > 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > than 2.2.) Patients with a negative or equivocal overall result (FISH test ratio of ≤ 2.2, ≤ 6.0 HER2 gene copies per nucleus) and staining scores of 0, 1+, 2+ or 3+ (in 30% or less neoplastic cells) by IHC are not eligible for participation in the trial.</li></ul><p>Equivocal local results may be submitted for a final determination by the central laboratory.</p><ul><li>Completion of all necessary baseline laboratory and radiological investigations</li><li>Signed written informed consent (approved by an Independent Ethics Committee (IEC) and obtained prior to any study specific screening procedures).</li></ul><p>Exclusion Criteria:</p><ul><li>History of any prior (ipsi- and/or contralateral) invasive breast carcinoma;</li><li>Past (less than 10 years) or current history of malignant neoplasms, except for curatively treated 1) basal and squamous cell carcinoma of the skin or 2) carcinoma in situ of the cervix.</li></ul><p>NOTE: Patients with a prior malignancy diagnosed greater than 10 years in the past who have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic therapy (chemotherapy or endocrine) are eligible for the study.\nPatients with any prior diagnosis of breast cancer or melanoma, at any time, are excluded from this study.</p><ul><li>Any clinically staged T4 tumour, including inflammatory breast cancer;</li><li>Bilateral tumours;</li><li>This exclusion criterion has been removed as of protocol amendment 1.</li></ul><p>NOTE: multifocal/multicentric tumours are permitted:</p><ul><li>If the patient is node-negative: one of the lesions must be equal or greater than 1.0 cm (sum of the lesion diameters is not acceptable) AND must have positive HER2 status centrally-confirmed;</li><li>If patient is node-positive: lesion size does not matter BUT one of the lesions must have HER2 positivity centrally-confirmed.\nIf several lesions are found to be HER2 positive locally, the largest lesion should be considered for central review.</li><li>Maximum cumulative dose of doxorubicin >360mg/m² or maximum cumulative dose of epirubicin >720mg/m² or any prior anthracyclines unrelated to the present breast cancer;</li><li>(Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell support;</li><li>Any prior mediastinal irradiation except internal mammary node irradiation for the present breast cancer;</li><li>Patients with positive or suspicious internal mammary nodes identified by sentinel node technique which have not been irradiated or will not be irradiated, or patients with supraclavicular lymph node involvement (confirmed by fine needle aspirate or biopsy);</li><li>Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for breast cancer;</li><li>Concurrent anti-cancer treatment, except hormonal therapy or radiotherapy for the present breast cancer;</li><li>Concurrent anti-cancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the Executive Committee:</li><li>Serious cardiac illness or medical conditions including but not confined to:</li></ul><p>History of documented congestive heart failure (CHF) or systolic dysfunction (LVEF <50%); High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled); Angina pectoris requiring antianginal medication; Clinically significant valvular heart disease; Evidence of transmural infarction on ECG; Poorly controlled hypertension (e.g.\nsystolic >180mm Hg or diastolic >100mm Hg);</p><ul><li>Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness;</li><li>Any of the following abnormal laboratory tests immediately prior to randomization:</li></ul><p>serum total bilirubin >1.5 x upper limit of normal (ULN), in the case of known Gilbert's syndrome, a higher serum total bilirubin (<2 X ULN) is allowed; alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) >2.5 x ULN; alkaline phosphatase (ALP) > 2.5 x ULN; serum creatinine >2.0 x ULN; total white blood cell count (WBC) <2.5 x 10^9/L; absolute neutrophil count <1.5 x 10^9/L; platelets <100 x 10^9/L.</p><ul><li>Unresolved or unstable serious adverse events from prior adjuvant chemotherapy or radiotherapy;</li><li>Malabsorption syndrome, any disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication.\nSubjects with ulcerative colitis are also excluded;</li><li>Pregnant, lactating or women of childbearing potential without a negative pregnancy test - urine or serum - within 7 days prior to randomization, irrespective of the method of contraception used, including tubal ligation;</li><li>Women of childbearing potential and male participants with partners of child bearing potential, including women whose last menstrual period was <12 months ago (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during study treatment (adequate contraceptive measures: intra-uterine device, barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence.\nOral, injectable, or implant hormonal contraceptives are not indicated in this patient population);</li><li>Concomitant use of CYP3A4 inhibitors or inducers.</li></ul>"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/7",
"value": {
"zip": "72401",
"city": "Jonesboro",
"state": "Arkansas",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.8423,
"lon": -90.70428
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/9"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/15",
"value": {
"zip": "94538",
"city": "Fremont",
"state": "California",
"status": "COMPLETED",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 37.54827,
"lon": -121.98857
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/17"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/21",
"value": {
"zip": "92093-0987",
"city": "La Jolla",
"state": "California",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 32.84727,
"lon": -117.2742
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/23"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/33/status",
"value": "COMPLETED"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/50",
"value": {
"zip": "80220",
"city": "Denver",
"state": "Colorado",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 39.73915,
"lon": -104.9847
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/52"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/81",
"value": {
"zip": "33805",
"city": "Lakeland",
"state": "Florida",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 28.03947,
"lon": -81.9498
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/83"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/103",
"value": {
"zip": "30165",
"city": "Rome",
"state": "Georgia",
"status": "COMPLETED",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 34.25704,
"lon": -85.16467
}
}
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/105/status",
"value": "NOT_YET_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/105/city",
"value": "Savannah"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/105/zip",
"value": "31405"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/105/geoPoint/lat",
"value": 32.08354
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/105/geoPoint/lon",
"value": -81.09983
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/107"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/124",
"value": {
"zip": "60611",
"city": "Chicago",
"state": "Illinois",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.85003,
"lon": -87.65005
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/126"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/149",
"value": {
"zip": "61350",
"city": "Ottawa",
"state": "Illinois",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.34559,
"lon": -88.84258
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/151"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/156",
"value": {
"zip": "61615",
"city": "Peoria",
"state": "Illinois",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 40.69365,
"lon": -89.58899
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/158"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/159",
"value": {
"zip": "61354",
"city": "Peru",
"state": "Illinois",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.32753,
"lon": -89.12897
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/161"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/172",
"value": {
"zip": "46202",
"city": "Indianapolis",
"state": "Indiana",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 39.76838,
"lon": -86.15804
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/174"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/183",
"value": {
"zip": "52722",
"city": "Bettendorf",
"state": "Iowa",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.52448,
"lon": -90.51569
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/185"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/191",
"value": {
"zip": "50314",
"city": "Des Moines",
"state": "Iowa",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 41.60054,
"lon": -93.60911
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/193"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/230",
"value": {
"zip": "70809",
"city": "Baton Rouge",
"state": "Louisiana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 30.44332,
"lon": -91.18747
}
}
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/232",
"value": {
"zip": "70112",
"city": "New Orleans",
"state": "Louisiana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 29.95465,
"lon": -90.07507
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/234"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/236",
"value": {
"zip": "04074",
"city": "Scarborough",
"state": "Maine",
"status": "COMPLETED",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 43.57814,
"lon": -70.32172
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/238"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/265/status",
"value": "RECRUITING"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/268",
"value": {
"zip": "49007",
"city": "Kalamazoo",
"state": "Michigan",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 42.29171,
"lon": -85.58723
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/270"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/276",
"value": {
"zip": "49085",
"city": "Saint Joseph",
"state": "Michigan",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 42.10976,
"lon": -86.48002
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/278"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/285",
"value": {
"zip": "55805",
"city": "Duluth",
"state": "Minnesota",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 46.78327,
"lon": -92.10658
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/287"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/299",
"value": {
"zip": "56303",
"city": "Saint Cloud",
"state": "Minnesota",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 45.5608,
"lon": -94.16249
}
}
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/301/status",
"value": "NOT_YET_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/301/city",
"value": "Saint Louis Park"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/301/zip",
"value": "55416"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/301/geoPoint/lat",
"value": 44.9483
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/301/geoPoint/lon",
"value": -93.34801
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/303"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/333",
"value": {
"zip": "63141",
"city": "St Louis",
"state": "Missouri",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 38.62727,
"lon": -90.19789
}
}
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/335/city",
"value": "Billings"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/335/state",
"value": "Montana"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/335/zip",
"value": "59101"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/335/geoPoint/lat",
"value": 45.78329
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/335/geoPoint/lon",
"value": -108.50069
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/337"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/339",
"value": {
"zip": "59405",
"city": "Great Falls",
"state": "Montana",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.50024,
"lon": -111.30081
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/341"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/374",
"value": {
"zip": "08240",
"city": "Pomona",
"state": "New Jersey",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 39.47845,
"lon": -74.57516
}
}
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/381",
"value": {
"zip": "87106",
"city": "Albuquerque",
"state": "New Mexico",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.08449,
"lon": -106.65114
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/383"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/393",
"value": {
"zip": "11030",
"city": "Manhasset",
"state": "New York",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 40.79788,
"lon": -73.69957
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/395"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/416",
"value": {
"zip": "27607",
"city": "Raleigh",
"state": "North Carolina",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.7721,
"lon": -78.63861
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/418"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/422",
"value": {
"zip": "58501",
"city": "Bismarck",
"state": "North Dakota",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 46.80833,
"lon": -100.78374
}
}
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/424/city",
"value": "Fargo"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/424/zip",
"value": "58122"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/424/geoPoint/lat",
"value": 46.87719
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/424/geoPoint/lon",
"value": -96.7898
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/426"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/537",
"value": {
"zip": "38301",
"city": "Jackson",
"state": "Tennessee",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 35.61452,
"lon": -88.81395
}
}
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/539/city",
"value": "Knoxville"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/539/zip",
"value": "37909"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/539/geoPoint/lat",
"value": 35.96064
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/539/geoPoint/lon",
"value": -83.92074
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/541"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/556/status",
"value": "RECRUITING"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/593",
"value": {
"zip": "98122",
"city": "Seattle",
"state": "Washington",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.60621,
"lon": -122.33207
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/595"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/599",
"value": {
"zip": "98405",
"city": "Tacoma",
"state": "Washington",
"status": "RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.25288,
"lon": -122.44429
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/601"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/615",
"value": {
"zip": "54301",
"city": "Green Bay",
"state": "Wisconsin",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 44.51916,
"lon": -88.01983
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/617"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/624",
"value": {
"zip": "53233",
"city": "Milwaukee",
"state": "Wisconsin",
"status": "NOT_YET_RECRUITING",
"country": "United States",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 43.0389,
"lon": -87.90647
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/626"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/702",
"value": {
"zip": "9000",
"city": "Ghent",
"status": "COMPLETED",
"country": "Belgium",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 51.05,
"lon": 3.71667
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/704"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/789/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/790/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/791/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/792/status",
"value": "COMPLETED"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/793/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/795/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/796/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/797/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/798/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/800/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/801/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/802/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/804/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/805/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/806/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/807/status",
"value": "COMPLETED"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/808/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/810/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/812/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/813/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/816/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/817/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/818/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/819/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/820/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/821/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/822/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/824/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/825/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/826/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/828/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/829/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/830/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/831/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/832/status",
"value": "COMPLETED"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/834/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/835/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/838/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/839/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/840/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/841/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/842/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/843/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1051/status",
"value": "COMPLETED"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1052/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1053/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1054/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1055/status",
"value": "COMPLETED"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1056/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1143/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1145/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1146/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1148/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1150/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1151/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1152/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1153/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1155/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1158/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1159/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "replace",
"path": "/protocolSection/contactsLocationsModule/locations/1160/status",
"value": "ACTIVE_NOT_RECRUITING"
},
{
"op": "add",
"path": "/protocolSection/contactsLocationsModule/locations/1293",
"value": {
"zip": "8091",
"city": "Zurich",
"status": "NOT_YET_RECRUITING",
"country": "Switzerland",
"facility": "GSK Investigational Site",
"geoPoint": {
"lat": 47.36667,
"lon": 8.55
}
}
},
{
"op": "remove",
"path": "/protocolSection/contactsLocationsModule/locations/1295"
}
]